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Anneke J Kievit10, Virginie JM Verhoeven4,10, Jan WR Pott11, Suzanne CEH Sallevelt12,
Johanna M van Hagen13, Astrid S Plomp14, Hester Y Kroes15, Stefan H Lelieveld1,2, Jayne Y Hehir-Kwa1,2,
Steven Castelein1,2, Marcel Nelen1,2, Hans Scheffer1,2, Dorien Lugtenberg1,2, Frans PM Cremers1,2,
Lies Hoefsloot10 and Helger G Yntema*,1,2
Inherited eye disorders have a large clinical and genetic heterogeneity, which makes genetic diagnosis cumbersome. An exome-
sequencing approach was developed in which data analysis was divided into two steps: the vision gene panel and exome
analysis. In the vision gene panel analysis, variants in genes known to cause inherited eye disorders were assessed for
pathogenicity. If no causative variants were detected and when the patient consented, the entire exome data was analyzed.
A total of 266 Dutch patients with different types of inherited eye disorders, including inherited retinal dystrophies, cataract,
developmental eye disorders and optic atrophy, were investigated. In the vision gene panel analysis (likely), causative variants
were detected in 49% and in the exome analysis in an additional 2% of the patients. The highest detection rate of (likely)
causative variants was in patients with inherited retinal dystrophies, for instance a yield of 63% in patients with retinitis
pigmentosa. In patients with developmental eye defects, cataract and optic atrophy, the detection rate was 50, 33 and 17%,
respectively. An exome-sequencing approach enables a genetic diagnosis in patients with different types of inherited eye
disorders using one test. The exome approach has the same detection rate as targeted panel sequencing tests, but offers a
number of advantages. For instance, the vision gene panel can be frequently and easily updated with additional (novel) eye
disorder genes. Determination of the genetic diagnosis improved the clinical diagnosis, regarding the assessment of the
inheritance pattern as well as future disease perspective.
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INTRODUCTION
Inherited eye disorders are an important cause of visual impairment in
children and working age people in the Western world.1,2 Within the
spectrum of inherited eye disorders, a large clinical heterogeneity is
observed. Among the most frequently observed hereditary eye diseases
are inherited retinal dystrophies (IRDs), with an incidence of
approximately 2.5 in 10 000.1–3 In patients with IRDs rod photo-
receptors, cone photoreceptors and/or retinal pigment epithelial cells
degenerate due to monogenic inheritance of highly penetrant disease-
causing genetic variants.4 Using clinical features, IRDs are divided
into a wide array of clinical subtypes, such as retinitis pigmentosa,
Leber congenital amaurosis and so on.4 Another frequent here-
ditary eye disorder is congenital and childhood cataract with a
cumulative incidence of 3.5 per 10 000 at age 15 years.1,2,5 Only half
of the congenital and childhood cataract has a genetic origin.6
Developmental eye defects and optic atrophy are less frequent among
the inherited eye disorders.1 The clinical heterogeneity of inherited eye
disorders is even more complex, as they can manifest as an isolated eye
disorder or can be part of a syndrome with involvement of additional
organs.4 For instance, patients with Bardet–Biedl syndrome have,
besides retinal dystrophy, also skeletal, genitourinary and neurological
symptoms.7
Determination of the genetic cause of inherited eye disorders has a
signiﬁcant clinical relevance. In Western countries, most patients are
the only affected individual in their family, making it impossible to
determine the exact inheritance pattern and recurrence risk in
offspring. With a genetic diagnosis, accurate genetic counseling can
be provided and prenatal testing can be offered.8 Furthermore, for
patients to become eligible for genetic therapies that target speciﬁc
disease genes, their genetic disease cause must be known.9 Moreover,
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in multiple syndromes the manifestation of the eye disorder is the ﬁrst
detectable symptom, for instance in the metabolic syndrome galacto-
kinase deﬁciency.10 Genetic testing can give a diagnosis at an early
stage and, if available, preventive measures and treatment can start
before other symptoms have developed.11
Within the different inherited eye disorders, a large genetic
heterogeneity is present. Variants in more than 200 genes have been
described to cause IRDs and variants in more than 100 genes have
been associated with cataract.11,12 Because in many eye disorders there
is no single gene that accounts for disease in the majority of patients,
the detection of the underlying genetic defect by Sanger sequencing is
time consuming and expensive and is often not feasible. Since the
introduction of next-generation sequencing, many different targeted
gene panel tests that sequence a large set of disease-associated genes in
one experiment have been developed for speciﬁc inherited eye
disorders.13 The targeted sequencing tests have a far higher diagnostic
yield compared with previous genetic tests, such as Sanger
sequence.11,13,14 These tests, however, target only a subset of the
inherited eye disorders and therefore for each disease category a gene
panel test needs to be developed; moreover, for every update the test
needs to be validated and patients need to be retested. In contrast,
exome sequencing allows the determination of a genetic diagnosis for
all types of inherited eye disorders in one single test and when a new
panel is implemented, a bioinformatics re-analysis of the already
available data is sufﬁcient. The aim of this study was to determine
whether exome sequencing in a diagnostic setting is a good method to
provide a genetic diagnosis, and to assess the detection rate of
causative variants in Dutch patients with inherited eye disorders.
SUBJECTS AND METHODS
Subjects and clinical evaluation
This study was approved by the institutional review boards of the Radboud
University Medical Center and adhered to the tenets of the Declaration of
Helsinki. Informed consent was obtained from all the participants. A cohort of
266 patients with visual impairment diagnosed by different medical centers in
the Netherlands were included in this study. The speciﬁc eye disorders were
diagnosed by expert ophthalmologists based on appropriate clinical
examinations.
The exome results of the patient with unique identiﬁer (UID)5085,15 and the
causative variants of the affected brother of UID4785 have already been
published.16
Exome sequencing
Sequencing of the exome was performed after the participants were counseled
by a clinical geneticist at one of the medical university centers located in the
Netherlands. DNA was extracted from peripheral blood using standard
procedures. In all 266 cases, exome enrichment was performed using Agilent’s
SureSelect XT Human All Exon V4 (Agilent Technologies, Santa Clara, CA,
USA). For 48 cases, next-generation sequencing was performed using a 5500xl
SOLiD System (Life Technologies) and data analysis was performed as
described previously.17 For 218 cases, next-generation sequencing was per-
formed using a Illumina HiSeq2000TM sequencer at BGI-Europe (Copenha-
gen, Denmark). Read alignment to the human reference genome (GrCH37/
hg19) and variant calling was performed at BGI using BWA and GATK
software, respectively. For all cases, variant annotation was performed using a
custom designed in-house annotation and variant prioritization pipeline. Copy
number analysis was performed in all cases using CoNIFER 0.2.0 software and
annotation was performed using an in-house strategy.
Exome analysis
The analysis of the exome data was divided into two steps: the vision gene panel
analysis and the exome analysis. In the vision gene panel analysis, an in silico
enrichment of genes associated with genetic eye disorders was performed. This
vision gene panel was updated three times during the 3-year period of this
study. Fifteen cases were analyzed with the v120612 version consisting of 164
genes, 22 cases were analyzed with version v220313 consisting of 194 genes, 196
cases were analyzed with version v200614 consisting of 273 genes and 33 cases
were analyzed with version v141114 consisting of 286 genes (Supplementary
Tables 1 and 2). In the vision gene panel analysis, variants in the panel genes
with a frequency below 5% in dbSNP and below 1% in an in-house database
(consisting of exome frequency data of mostly Dutch individuals) and within
the exon or within intronic position − 20 till +8 were interpreted and classiﬁed
based on existing guidelines for variant classiﬁcation that were determined by
the Association for Clinical Genetic Science (classiﬁcation range from class 1
benign till class 5 pathogenic).18,19 In the second step, the exome analysis, all
genes were analyzed. Protein truncating variants, missense variants with a
PhyloP above or equal to 3.5 and canonical splice site variants with a frequency
below 5% in dbSNP and below 1% in an in-house database were interpreted
and classiﬁed in the same way as in the vision gene panel analysis. In both steps
of the analysis, cases were grouped into distinct groups based on the variant
classiﬁcation, segregation analysis and associated phenotype known from
literature. Three groups were distinguished: cases with causative variant(s),
cases with likely causative variant(s) and cases in whom no causative variants
were detected. Cases were determined to have causative variant(s) when (i) the
detected variant arose de novo, (ii) the detected variant(s) segregated in the
family and the affected gene matched the described phenotype or (iii) when no
segregation was performed at least one of the detected variants was a published
pathogenic, a protein truncating or canonical splice site variant and the affected
gene matched the described phenotype. Cases were determined to have likely
causative variant(s) when the affected gene matched the described phenotype,
no segregation was performed and when a novel missense variant was present
in a gene causing autosomal dominant or X-linked inheritance, or when two
novel heterozygous missense variants or a novel homozygous missense variant
were present in a gene causing autosomal recessive inheritance. Cases were
determined to have no causative variants when (i) no pathogenic variants were
detected, (ii) one heterozygous variant was detected in a gene in which disease-
causing variants are associated with autosomal recessive inherited disease or (iii)
variant(s) did not segregate in the family. When no causative variant(s) were
detected in the vision gene panel analysis and when the patient consented for
this analysis, the second step, the exome analysis, was performed. The disease-
causing variants were submitted to ClinVar (submission ID: SUB1936409).
Sanger sequencing and MLPA
All reported single-nucleotide variants have been validated by Sanger sequen-
cing. Primers were developed using Primer3 software. Primers and PCR
conditions are available upon request. In 28 cases in whom only one (likely)
pathogenic variant was detected in a gene that is causing a recessive inherited
eye disorder all coding exons with ﬂanking introns and the splice sites of all
noncoding exons were Sanger sequenced. When pathogenic intronic and/or
copy number variants were described for the gene, Sanger sequencing of the
speciﬁc intronic regions (ABCA4 intron 31 and 36, CEP290 intron 26 or
USH2A intron 40), a deletion PCR (ABCA4 exon 20-22 deletion or USH2A
exon 38-56 deletion) and/or MLPA (ABCA4 MRC-Holland kit P151-B1, EYS
MRC-Holland kit P328-A1, or USH2A: MRC-Holland kits P361-A1 and P362-
A1) were also performed. Copy number variants detected in the exome data
were validated by MLPA (PANK2 MRC-Holland kit P120-B1, PAX6 MRC-
Holland kit P219-B2 or USH2A MRC-Holland kit P361-A1 and P362-A2),
deletion PCR (CLN3 exon 7-8 deletion) or genome-wide SNP array (PDE6B).
RESULTS
Patients
In this study, 266 Dutch probands with visual impairment, who were
referred for diagnostic exome sequencing in 2012, 2013 and 2014 to
the Department of Human Genetics of the Radboud University
Medical Center, were included. The patients had different types of
inherited eye disorders, with IRD as the most common (~90% of the
cases; Figure 1a). Furthermore, the cohort contained patients with
cataract, optic atrophy and developmental eye defects (Figure 1a). In
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12% of the cases, the eye disorder was part of a syndrome, for instance
Usher syndrome or Bardet–Biedl syndrome (Supplementary Table 2).
In most cases, the family had only one affected individual (simplex
cases), while in 13% an autosomal recessive, in 12% an autosomal
dominant and in 3% an X-linked inheritance was predicted based on
the family pedigree. In 12% of the cases the parents were consangui-
neous and in these families 24 cases were simplex and eight had
multiple affected siblings (Supplementary Table 2). In 63% of the
cases, one or more genetic tests were performed previously
(Supplementary Table 2).
Exome sequencing provides more than 20× coverage in most
inherited eye disease genes
The enrichment of the exome was not tailored speciﬁcally towards
inherited eye disease genes. To investigate whether the 298 genes of the
vision panels are well covered, we determined for each vision panel
gene the percentage of base pairs in the gene with an average coverage
of at least 20×, only including regions targeted for enrichment
(Supplementary Figures 1a and b). On the SOLiD platform, the
majority of genes in the vision panel genes achieved a mean coverage
above 20× in 91 till 95% of the targeted gene region, while for the
HiSeq platform this was in 96 till 100% of the targeted gene region
(Figure 2, Supplementary Figures 1a and b).
To investigate the extent of possible false-negative results, we
determined for all 298 panel genes which exons had an average
coverage below 10× in 75% or more base pairs, including the regions
that are not targeted for enrichment. The majority of exons with a
coverage below 10× were not targeted for enrichment. Most of these
exons were noncoding, but also 35 exons with coding sequence were
not targeted (Supplementary Table 3). For instance, all exons of the
OPN1LW and OPN1MW gene were not targeted, because of their high
homology. In 11 of the noncoding and 20 of the coding exons,
disease-causing variants have been described (Supplementary Table 3).
Furthermore, several exons were not efﬁciently enriched; on the
SOLiD platform, 136 targeted exons, and on the HiSeq platform, 15
targeted exons had a coverage below 10× in 75% of the base pairs. In
approximately half of these exons, pathogenic disease-causing variants
have been described (Supplementary Table 3).
Vision gene panel analysis determined (likely) causative variants in
49% of the cases
In the ﬁrst step of analysis of the exome data, the vision gene panel
analysis, variants in genes associated with inherited eye disorders were
analyzed. Most genes in the vision gene panel cause syndromic or
non-syndromic IRDs, but also genes associated with cataract, optic
atrophy and developmental eye disease are present (Figure 3a). In 122
cases (46%) causative variant(s), in nine cases (3%) likely causative
variant(s), and in 135 cases (51%) no causative variants were detected
(Supplementary Table 4). In seven cases, copy number analysis
of the exome data detected a causative duplication or deletion
(Supplementary Table 4). In 11 of the 122 cases in whom a (likely)
genetic cause was detected, the second allele was determined using a
second genetic test (Supplementary Table 4). These results are
discussed in more detail in the next paragraph. Three cases had
(likely) causative variants in two genes, that might have a synergistic
effect (Supplementary Table 4).
In 53 cases, the DNA of affected and/or unaffected family member(s)
was tested for segregation of the (likely) causative variant(s) in the
proband. In seven of these cases, the variant did not segregate within
the family (Table 1). In four simplex cases, a heterozygous variant in a
gene involved in autosomal dominant inheritance was also present in
one of the unaffected parents (BEST1, SNRNP200 and TEAD1) and in
three cases the variant(s) was/were absent in an affected family
member (BBS5, CRB1 and ZNF644; Table 1).
Figure 1 Clinical details of the 266 Dutch patients with visual impairment.
In our cohort of patients with visual impairment 13 different (sub)types of
inherited eye disorders were clinically diagnosed. Most cases had an IRD,
including 129 patients (49%) with retinitis pigmentosa, 44 patients (16%)
with cone or macular dystrophy, 30 patients (11%) with cone–rod dystrophy
and 15 patients (6%) with Leber congenital amaurosis. Furthermore, six
patients with cataract, six patients with developmental eye disorders,
including patients with aniridia, coloboma, microcornea and micro- or
nanopthalmos and six patients with optic atrophy were included. The group
of retinal dystrophies contained unspeciﬁed retinal dystrophies (n=20) and
rare forms of retinal dystrophies, including patients with benign concentric
annular macular dystrophy, bradyopsia, congenital stationary night blindness,
cystoid macular dystrophy, enhanced S-cone syndrome, foveal hypoplasia or
night blindness with retinal detachment.
Figure 2 Mean percentage base pairs covered by at least 20× of the vision
panel genes. For each of the 298 vision panel genes, the mean percentage
of base pairs covered by at least 20× of the targeted gene region was
calculated for all 48 samples on the SOLiD and for all 218 cases run on the
HiSeq platform. On both platforms, most genes had a mean percentage of
base pairs covered by at least 20× in the range of 91 till 100%. However, if
this range is further dissected, the SOLiD platform had most genes in the
range of 91 till 95%, while for the HiSeq platform this was in the range of
96 till 100%. Furthermore, the HiSeq platform had only three genes with a
mean percentage of base pairs covered by at least 20× below 70%, while
for the SOLiD platform this was the case in 65 genes.
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In the vision gene panel analysis (likely) causative variants were
identiﬁed in 56 different genes (Figure 3b). USH2A was most often the
causative gene, while 31 genes were causative in single cases
(Figure 3b). In the 56 genes, 178 different variants were detected
(including variants identiﬁed in a second genetic test). Of the total 81
(46%) novel detected variants, 47 were either protein truncating or
canonical splice site variants (Supplementary Table 4). The majority of
variants (73%) was detected once, only three variants were detected
four times, namely BBS1 c.1169T4G, CRX c.205C4T and USH2A
c.2276G4T.
A subsequent genetic test identiﬁed the second causative allele in 11
of 32 tested cases
In 46 cases, the vision gene panel analysis detected one heterozygous
variant in a gene that is associated with an autosomal recessive
inherited eye disorder (Table 2). In 11 of 32 cases, subsequent test(s)
identiﬁed a second pathogenic variant (Table 2). Interestingly, in these
11 cases, the variant allele detected in the exome analysis was either a
known pathogenic variant, a protein truncating variant or a canonical
splice site variant (Table 2). In six cases, a (likely) pathogenic deep-
intronic variant (ABCA4 or CEP290) was identiﬁed. These variants
Figure 3 Vision gene panel revisions and genes carrying variants in the vision gene panel analysis. (a) The genes present in the vision gene panel were
grouped into seven main types of inherited visual impairment. In the 3-year time period of this study, the vision gene panel, used in the ﬁrst step of analysis,
was updated three times. The initial version of the panel consisted mostly of genes known to cause syndromic and/or non-syndromic IRD. In the second
update also genes known to cause syndromic and/or non-syndromic cataract or developmental eye defects were added. Furthermore, in each update, recently
published inherited eye disease genes were added. (b) In the vision gene panel analysis (likely) causative variants were detected in 56 different inherited eye
disease genes. USH2A, EYS, ABCA4 and RPGR carried most often the causative variant and taken together they are the responsible causative gene in more
than a quarter of the cases in whom a genetic cause was detected. The other genes were implicated to cause disease in 4% or less of the cases.
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were not present in the exome data, because deep-intronic regions are
not enriched. In four cases, a deletion or duplication of a small region
(50 bp or 1 exon) of either the EYS or the PDE6B gene was identiﬁed.
Copy number analysis performed on the exome data can only detect
deletions and duplications of at least three consecutive exons20 and,
therefore, these four small deletions were not identiﬁed. In the last
case, the second allele was a canonical splice site variant, not detected
in the exome data due to low coverage of the region in this case (nine
reads of which only two reads contained the variant nucleotide).
Analysis of the exome determined a (likely) genetic cause in ﬁve
additional cases
When no causative variants were identiﬁed in the vision gene panel
analysis, the analysis of the complete exome data was performed as a
second step. As there is a possibility of approximately 1% to have an
unsolicited ﬁnding in this analysis,21 for instance a disease-causing
BRCA1 variant, this second step was only performed in patients who
consented for this analysis. Consent to analyze the complete exome
was given by 79% of patients (106 of the 135 cases) with a negative
vision gene panel result. In this additional analysis, in three cases (3%)
causative variants and in three cases (3%) likely causative variants were
detected (Supplementary Table 4). Variants were identiﬁed in four
different genes. Disease-causing variants in two of these genes, POC1B
andMFSD8, were recently published to cause cone–rod dystrophy and
macular dystrophy, respectively.22,23 Consequently, these genes were
not yet in the vision gene panel version used for these cases. MFSD8
was added to vision gene panel v200614 and POC1B to v141114.
Likely disease-causing variants were detected in CEP83 in a patient
with apparent non-syndromic RP, while two of her siblings have
Senior–Loken syndrome. The last case had a de novo variant in the
KIF21A gene. Disease-causing variants in KIF21A cause a syndrome in
which the muscular symptoms are most apparent and this gene is
therefore not in the vision gene panel. In one case, it was concluded
that the frameshift variant in TFAP2A was not the cause of the disease,
because it was also present in the unaffected mother and grandfather
(Table 1).
The diagnostic yield is highest in cases with IRD
Taking the detection rate of causative variants of the vision gene panel
and exome analysis together, we determined (likely) causative variants
in 52% of the visual impairment cases. As already described in
literature, the detection rate differed considerably between the
different (sub)types of inherited eye disorders. The different subtypes
of IRDs had the highest detection rate. In all patients with achroma-
topsia and Stargardt disease (likely) causative variants were identiﬁed,
though for both a small number of cases were tested (Table 3). Of the
IRDs of which more than 10 cases were tested, Leber congenital
amaurosis and retinitis pigmentosa had the highest diagnostic yield,
60% and 63% respectively, and macular dystrophy and retinal
dystrophy (containing rare forms of retinal dystrophies and unspeci-
ﬁed retinal dystrophies) had the lowest detection rate of 28% and
25%, respectively (Table 3). Cases with developmental eye defects,
cataract and optic atrophy had a detection rate of 50%, 33% and 17%,
respectively (Table 3).
Genetic diagnosis redeﬁned the inheritance pattern and clinical
diagnosis
The great majority of our patients were the only affected individual in
their family, and in these simplex cases the inheritance pattern is
unclear without a genetic diagnosis. Of the simplex cases in whom
(likely) causative variants were identiﬁed, 88% had autosomal
recessive, 6% had autosomal dominant and 6% had X-linked
inheritance. The genetic diagnosis also redeﬁned the inheritance
pattern in cases in whom an inheritance pattern was predicted based
on the family pedigree. Three families, in which autosomal dominant
inheritance was predicted, actually had X-linked inheritance (RPGR),
one family with predicted autosomal recessive inheritance, the genetic
diagnosis determined dominant inheritance (the EYA1 variant was also
present in the mother with a very mild phenotype), and last, one
family with predicted X-linked inheritance showed an autosomal
recessive inheritance after genetic diagnosis (USH2A).
The genetic diagnosis also redeﬁned the clinical phenotype in three
cases. Case UID3855 with cone–rod dystrophy and case UID4088 with
retinitis pigmentosa had no clear signs of any additional clinical
symptoms except for a slight motor developmental delay in UID4088.
Exome sequencing identiﬁed in both cases causative variants in the
PANK2 gene that causes NBIA1 syndrome, which is also known to
express a broad range of neurological symptoms. In patients with
PANK2 variants, retinal dystrophy is one of the ﬁrst symptoms, and in
both cases the neurological symptoms of NBIA1 syndrome presented
Table 1 Variants determined to be non-causative after analysis of affected and/or unaffected family members
Detected variant(s)
UID Eye phenotype Gene Allele 1 Detected in Result segregation analysis
1385 Cone–rod dystrophy BBS5 NM_152384.2 c.92T4C
c.92T4C
p.(Ile31Thr)
p.(Ile31Thr)
Blind panel analysis Affected brother has the variant
heterozygous
3026 Macular dystrophy BEST1 NM_001139443.1 c.1223C4T p.(Pro408Leu) Blind panel analysis Unaffected mother has the variant
8732 Macular dystrophy CRB1 NM_201253.2 c.1023T4A
c.3713_3716dup
p.(Asn341Lys)
p.(Cys1240fs)
Blind panel analysis Affected sister carries both variants,
affected brother doesn't carry any of the
variants
6217 Retinitis pigmentosa SNRNP200 NM_014014.4 c.4835C4T p.(Thr1612Met) Blind panel analysis Unaffected father has the variant
8681 Cone–rod dystrophy SNRNP200 NM_014014.4 c.5644C4A p.(Pro1882Thr) Blind panel analysis Unaffected mother has the variant
9722 Macular dystrophy TEAD1 NM_021961.5 c.59G4A p.(Ser20Asn) Blind panel analysis Unaffected father has the variant
8239 Iris and choroid coloboma TFAP2A NM_003220.2 c.723del p.(Glu242fs) Exome analysis Affected brother, unaffected mother and
unaffected grandfather have the variant
1728 Benign concentric annular
macular dystrophy
ZNF644 NM_201269.1 c.3031C4G p.(Gln1011Glu) Blind panel analysis Affected father does not have
the variant
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Table 2 Cases with a single heterozygous (likely) causative variant in a gene causing recessive disease
Detected variant(s)
UID Eye phenotype Gene Transcript ID Allele Result additional genetic test(s)
7762 Stargardt disease ABCA4 NM_000350.2 c.1822T4A p.(Phe608Ile)a Deep-intronic variant c.5196+1137G4A detected
4459 Stargardt disease ABCA4 NM_000350.2 c.3113C4T p.(Ala1038Val)a Deep-intronic variant c.4539+2001G4A detected
4913 Retinitis pigmentosa ABCA4 NM_000350.2 c.3113C4T p.(Ala1038Val)a No second variant
0732 Retinitis pigmentosa ABCA4 NM_000350.2 c.4771G4A p.(Gly1591Arg)a No second variant
4795Z Cone dystrophy ABCA4 NM_000350.2 c.5056G4A p.(Val1686Met)a No second variant
4182 Stargardt disease ABCA4 NM_000350.2 c.5584+6T4C r.(spl?)a Deep-intronic variant c.4539+2001G4A detected
2851 Cone–rod dystrophy ABCA4 NM_000350.2 c.5882G4A p.(Gly1961Glu)a ND
4261 Macular dystrophy ABCA4 NM_000350.2 c.6148G4C p.(Val2050Leu)a No second variant
0889 Stargardt disease ABCA4 NM_000350.2 c.634C4T p.(Arg212Cys)a Deep-intronic variant c.4539+2001G4A detected
3013 Retinitis pigmentosa ALMS1 NM_015120.4 c.6571_6574del p.(Ser2191fs) ND
USH2A NM_206933.2 c.11815G4A p.(Glu3939Lys)a ND
3988 Leber congenital
amaurosis
BBS1 NM_024649.4 c.1131_1135del p.(Cys377fs)a No second variant
5017 Retinitis pigmentosa BBS5 NM_152384.2 c.551A4G p.(Asn184Ser)a No second variant
3366 Retinitis pigmentosa C2ORF71 NM_001029883.1 c.530C4T p.(Pro177Leu) No second variant
CNGB1 NM_001297.4 c.2360A4G p.(Tyr787Cys) No second variant
3803 Leber congenital
amaurosis
CEP290
RPE65
NM_025114.3
NM_000329.2
c.1079G4A
c.676G4A
p.(Arg360Gln)
p.(Val226Ile)
No second variant
No second variant
5502 Leber congenital
amaurosis
CEP290 NM_025114.3 c.4960C4T p.(Gln1654*) Deep-intronic variant c.2991+1655A4G detected
8389 Retinitis pigmentosa CEP290 NM_025114.3 c.5649dup p.(Leu1884fs)a Deep-intronic variant c.2991+1655A4G detected
6858 Retinal dystrophy CEP290 NM_025114.3 c.6547C4T p.(His2183Tyr) No second variant
8120 Macular dystrophy CNGA3 NM_001298.2 c.1618G4A p.(Val540Ile)a ND
CDHR1 NM_033100.2 c.783G4A r.(spl?)a ND
0308 Retinitis pigmentosa EYS NM_001142800.1 c.1161del p.(Lys387fs) Copy number variant c.(2137+1_2138-1)_(2259+1_2260-1)dup
detected
2400 Retinitis pigmentosa EYS NM_001142800.1 c.5167_5168del p.(Leu1723fs) Copy number variant c.(6424+1_6425-1)_(6571+1_6572-1)del
detected
3982 Retinitis pigmentosa EYS NM_001142800.1 c.5167_5168del p.(Leu1723fs) Copy number variant c.(3243+1_3244-1)_(3443+1_3444-1)dup
detected
1073 Cone dystrophy KCNV2 NM_133497.3 c.820G4A p.(Val274Met) No second variant
5428 Retinal dystrophy LEPREL1 NM_018192.3 c.1906C4T p.(Pro636Ser) No second variant
3854 Cone–rod dystrophy MAK NM_001242957 c.941C4T p.(Pro314Leu) ND
5615 Cone dystrophy MFRP NM_031433.3 c.855T4A p.(Cys285*) No second variant
2666 Developmental eye
defect
MKS1 NM_017777.3 c.857A4G p.(Asp286Gly)a No second variant
4368 Macular dystrophy NMNAT1 NM_022787.3 c.769G4A p.(Glu257Lys)a No second variant
9731 Cone–rod dystrophy NR2E3 NM_014249.2 c.724_725del p.(Ser242fs) Second variant c.119-2A4C detected
4795B Retinal dystrophy OCA2 NM_000275.2 c.1025A4G p.(Tyr342Cys)a ND
0235 Retinitis pigmentosa PDE6B NM_000283.3 c.(?_-53)_(*785_?)
del
p.0 No second variant
6317 Retinitis pigmentosa PDE6B NM_000283.3 c.1210A4G p.(Arg404Gly) ND
6488 Retinitis pigmentosa PDE6B NM_000283.3 c.2193+1G4A r.(spl?)a Copy number variant c.1923_1971delinsTCTGGGTA detected
8843 Retinitis pigmentosa PDE6B NM_000283.3 c.2503+5G4C r.(spl?)a ND
7248 Cone dystrophy RLBP1 NM_000326.4 c.454G4A p.(Asp152Asn) ND
8369 Retinitis pigmentosa RP1 NM_006269.1 c.2005G4A p.(Ala669Thr)a ND
2438 Retinitis pigmentosa RP1 NM_006269.1 c.368_369dup p.(Pro124fs)a No second variant
4698 Retinitis pigmentosa RP1 NM_006269.1 c.368_369dup p.(Pro124fs)a ND
9807 Retinitis pigmentosa RP1 NM_006269.1 c.4961C4T p.(Ser1654Phe) ND
MAK NM_005906.4 c.383C4A p.(Pro128Gln) ND
0459 Retinitis pigmentosa RP1L1 NM_178857.5 c.1153C4T p.(Arg385Trp) ND
9088 Retinitis pigmentosa USH1G NM_173477.4 c.83C4T p.(Pro28Leu) No second variant
1428 Retinitis pigmentosa USH2A NM_206933.2 c.10510C4G p.(Pro3504Ala)a No second variant
2681 Retinitis pigmentosa USH2A NM_206933.2 c.12823T4A p.(Ser4275Thr) ND
0731 Cone–rod dystrophy USH2A NM_206933.2 c.15427C4T p.(Arg5143Cys)a ND
8964 Retinitis pigmentosa USH2A NM_206933.2 c.1582G4A p.(Asp528Asn) No second variant
8481 Retinitis pigmentosa USH2A NM_206933.2 c.5516T4A p.(Val1839Glu) No second variant
CDH23 NM_022124.5 c.5563C4T p.(Pro1855Ser) No second variant
9593 Retinitis pigmentosa USH2A NM_206933.2 c.5698T4G p.(Cys1900Gly) No second variant
Abbreviation: ND, not determined.
aVariant already described to cause an inherited eye disorder.
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in a later stage. The same holds true for case UID0504 with retinitis
pigmentosa, in whom causative variants were detected in CLN3, which
causes the progressive neurodegenerative disease neuronal ceroid
lipofuscinosis. The patient developed the neurological symptoms
later on.
DISCUSSION
We performed a single genetic test, exome sequencing, in a diagnostic
setting to identify disease-causing variants in 266 patients with
different types of inherited eye disorders. Using this single test, a
(likely) genetic cause was determined in 52% of the cases.
In our approach, the exome data analysis was divided into two
parts, the vision gene panel and the exome analysis. This two-step
analysis has two major advantages. First, the variant analysis was
optimized for the requirements of each step. Within the vision gene
panel analysis, variant frequency was the only exclusion criteria before
variants were assessed for pathogenicity, while in the exome analysis
additional criteria are used to keep the amount of variants that need to
be assessed within workable range. Second, for the exome analysis
step, patients must consent for unsolicited ﬁndings, such as disease-
causing BRCA1 variants. In the cohort, 21% of the cases did not
consent and if the complete exome would be analyzed directly, this
test would not be suitable for at most a quarter of the patients.
Exome sequencing was performed on two different platforms,
SOLiD and HiSeq, and both provide a coverage above 20× for most
vision panel genes. Yet the HiSeq platform outperformed the SOLiD
platform signiﬁcantly on uniformity and depth of coverage. Never-
theless, there were regions of the vision panel genes that were
persistently not covered in our cohort. First, some regions of the
vision panel genes were difﬁcult to enrich. Huang et al. determined
that next-generation sequencing has the potential to miss causative
variants in the RPGR gene, accounting for 70–75% of X-linked
retinitis pigmentosa cases.24 In the currently described exome
approach, most of the RPGR gene had a coverage above 20×, but
approximately 30% of the RPGR-ORF15 exon 15, a mutation hotspot
region, had less than 10× coverage. Nevertheless, the RPGR gene was
the fourth most frequently mutated gene in our cohort, demonstrating
that our approach is able to detect causative RPGR variants. In general,
newer versions of the enrichment kit and longer read lengths could
overcome enrichment difﬁculties. For instance, the OPN1LW and
OPN1MW genes are enriched in Agilent enrichment kit V5, while this
was not the case in V4 used in this study. Second, via an exome-
sequencing approach, deep-intronic and small copy number variations
(~50 bp till 2 exons) are not detected. In our cohort, an additional
genetic test identiﬁed a deep-intronic variant (n= 6) or a small copy
number variant (n= 4) as the second causative variant. We therefore
conclude that in our exome-sequencing approach, an additional
genetic test to identify variants in non-covered regions should be
performed, when a single heterozygous pathogenic variant is detected
in a gene associated with autosomal recessive inheritance. Unfortu-
nately, patients in whom all causative variants are in poorly/non-
covered region will not be genetically solved using the currently
described exome approach. To provide the best care for patients with
hereditary eye disorders, we developed a diagnostic ﬂow-scheme to
perform speciﬁc genetic tests, either as pre-screen, parallel to exome
sequencing, or after a negative exome result (Figure 4). In two cases of
our cohort, a subsequent genetic test identiﬁed the causative variant.
In UID5265 with LCA, the deep-intronic c.2991+1655A4G in
CEP290 was homozygously present and in UID8627 with cone–rod
dystrophy the complete OPN1MW gene was deleted. In two of the 13
simplex males with retinitis pigmentosa in whom the exome analysis
was negative, RPGR was Sanger sequenced and no causative variants
were detected. Each diagnostic laboratory needs to decide whether a
pre-screen (as suggested in the ﬂow-scheme) or simultaneous exome
sequencing and testing of intronic disease-causing variants/non-
covered regions is the most cost-effective approach with a reasonable
turnaround time in their situation.
The vision gene panel analysis detected (likely) causative variants in
49% of the visual impairment cases. It has to be noted that 63% of our
cases had pre-screening of one or more genetic tests, and when exome
sequencing is performed as the ﬁrst test the diagnostic yield will most
likely further increase with 5 till 15%. Furthermore, we hypothesize
that several of the 14 cases with one heterozygous variant in a gene
involved in a recessive disease would have been solved when genetic
follow-up was performed. In the vision gene panel analysis, variants
were identiﬁed in 56 different genes, of which 31 genes were causative
in single cases, and 46% of the identiﬁed variants were novel. This
strengthens the hypothesis that a diagnostic test for inherited eye
disorders has to have a broad genetic range and should not be
restricted to known disease-causing variants. In the exome analysis,
(likely) causative variants were detected in an additional 2% of the
patients. In four of the six cases, the causative variants resided in a
recently published gene (MFSD8 and POC1B) associated with
inherited eye disorder, indicating the importance to update gene
panels for inherited eye disorders in a regular manner. Our vision gene
panel can be adjusted without changing the actual test itself and in this
study the panel was updated three times. For targeted gene-sequencing
techniques, a frequent update is far more complicated, because new
probes/primers have to be developed and the enrichment has to be
optimized for every update. In addition, in contrast to targeted gene
sequencing, exome sequencing enables data to be periodically reana-
lyzed with a newer version of the vision gene panel, making it possible
to determine the genetic cause in a novel eye disease gene within the
already available data.
The past few years, multiple targeted gene panel tests have been
developed. The targeted gene panels for subtypes of IRDs have a
detection rate of approximately 50–70%.25 In our exome approach,
most of the IRD subtypes have a detection rate within this range. Only
the macular dystrophy and retinal dystrophy cases (containing rare
Table 3 Detection rate of (likely) causative variants per visual
impairment (sub)type
(Sub)type of visual impairment Total number of cases
Percentage of cases
with (likely) causative
variants (%)
Achromatopsia 2 100
Stargardt disease 5 100
Retinitis pigmentosa 129 63
Leber congenital amaurosis 15 60
Developmental eye defect 6 50
Cone dystrophy 19 47
Cone–rod dystrophy 30 43
Cataract 6 33
Macular dystrophy 25 28
Retinal dystrophy 20 25
Optic atrophy 6 17
Glaucoma 2 0
Myopia 1 0
Total 266 52
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forms of retinal dystrophies and unspeciﬁed retinal dystrophies) had a
far lower detection rate of 28% and 25%, respectively. For the macular
dystrophy, this was most likely due to the fact that almost all cases
were prescreened for ABCA4 and PRPH2, the most frequently mutated
genes in macular dystrophy. For retinal dystrophy, this was most likely
due to the fact that many of the disease-causing genes are not
yet known.
Only 50% of the congenital and childhood cataract is caused due to
a monogenetic cause. Interestingly, in our cohort only in the cases
with multiple affected family members a genetic cause was identiﬁed.
Moreover, Gillespie et al. had a detection rate of 75% using a targeted
gene sequencing method for congenital and childhood cataract.11
Indicating that strict patient inclusion criteria can increase the
diagnostic yield in patients with childhood and congenital cataract.
As shown in the current and previous exome studies, even if the
complete exome is analyzed the underlying genetic defect is not
detected in all patients. Apart from the fact that there might be
patients in whom the eye disorder is actually not genetic, there are
several reasons for missing the causative variants in hereditary cases.
This is, for instance, because in an increasing number of genes
pathogenic variants are described to be present in noncoding gene
regions. These variants are not present in exome-sequencing data, but
will be detected when whole genome sequencing is introduced into
patient care. Another important reason is that not all inherited eye
disorder genes are known. It is difﬁcult to identify candidate genes for
inherited eye disorders as the genes with the highest disease-causing
variant load have already been discovered. When a candidate gene is
found to be mutated in a single family or even in a simplex case, the
involvement of this gene in the inherited eye disorder must be further
investigated. Besides gaining more insight in the role of this gene in
the eye by functional testing and/or animal models, variant screening
of the gene in large cohorts of unsolved patients with an overlapping
phenotype is important. As there is an increasing number of
laboratories performing exome sequencing, data sharing would facil-
itate the detection of novel inherited eye disorder genes.
In 48% of the simplex cases, (likely) causative variant(s) were
detected and therefore in these patients the inheritance pattern and
recurrence risk could be determined. Furthermore, the frequency of
inheritance patterns determined in the cases in which a genetic cause
was identiﬁed, can be used as an empirical risk in the genetic
counseling of simplex cases in whom no genetic cause is known.
Remarkably, in 7% of the cases in whom an X-linked, autosomal
recessive or autosomal dominant inheritance pattern was predicted
based on the family pedigree, the genetic diagnosis determined a
different inheritance pattern. Besides the inheritance pattern, the
genetic diagnosis also redeﬁned the clinical diagnosis in three cases.
All cases were thought to have a non-syndromic eye disorder, but
genetic analysis revealed the presence of a syndromic disease, either
NBIA1 or neuronal ceroid lipofuscinosis. Unfortunately, no treatment
is available for these syndromes, but the early discovery was used to
inform the patients and their families about the prognosis of these
relatively severe syndromes. This demonstrates the importance of a
thorough pre-test counseling even when the analysis is restricted to the
vision gene panel.
In summary, our exome analysis approach for inherited eye
disorders is a good diagnostic test to determine the genetic diagnosis
in patients with inherited eye disorders and offers a number of
advantages over targeted panel sequencing. Moreover, determining the
Figure 4 Flow-scheme of genetic tests that should be performed in patients with inherited eye disorders. In our exome approach, some regions of genes
associated with inherited eye disorders have consistently low or no coverage. For instance, regions with high homology, GC-rich regions and repetitive regions
are difﬁcult to enrich. Moreover, deep-intronic and small copy number variations are not detected via an exome-sequencing approach. To provide the best
care, a diagnostic ﬂow-scheme speciﬁc for our exome approach was developed, to provide an overview in which types of inherited eye disorders a genetic test
should be performed as a pre-screen or after a negative exome result. In patients with Leber congenital amaurosis, Stargardt disease, X-linked retinitis
pigmentosa, blue cone monochromacy, Bornholm eye disease and albinism, a genetic pre-screen of one or two speciﬁc genes is indicated. In simplex male
patients with retinitis pigmentosa or cone–rod dystrophy and in patients with X-linked cone–rod dystrophy, a genetic follow-up test of one or two speciﬁc
genes is indicated after a negative exome result. In patients in whom a single heterozygous pathogenic variant is detected in a gene associated with
autosomal recessive inheritance, it is indicated to test the non-covered regions of that gene.
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genetic cause in patients with inherited eye disorders complements
clinical diagnosis both on inheritance pattern as well as future disease
prospective.
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